Comparative Pharmacology

Head-to-head clinical analysis: AZITHROMYCIN versus R P MYCIN.

Peer-Reviewed Evidence

Differential Analysis

AZITHROMYCIN vs R-P MYCIN

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

AZITHROMYCIN

Macrolide Antibiotic

Category A/B

R-P MYCIN

Macrolide Antibiotic

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

Binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting mRNA translation and thus protein synthesis. Exhibits concentration-dependent bactericidal activity.

R-P MYCIN is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, specifically at the 23S rRNA of the peptidyl transferase center. This action blocks the translocation step, thereby preventing the elongation of the peptide chain.

Clinical Dosing

500 mg orally once daily for 3 days, or 500 mg IV once daily for at least 2 days followed by 500 mg orally to complete 7-10 days of therapy for community-acquired pneumonia. For other indications, typical adult dose is 500 mg orally on day 1 then 250 mg orally once daily on days 2-5.

Rifampin 600 mg orally once daily or 10 mg/kg intravenously once daily.

Direct Interaction

None Documented

Other Significant Interactions

Clinical Note

moderate

Azithromycin + Norfloxacin

"Azithromycin may increase the QTc-prolonging activities of Norfloxacin."

Clinical Note

moderate

Azithromycin + Ibandronate

"Azithromycin may increase the QTc-prolonging activities of Ibandronate."

Clinical Note

moderate

Azithromycin + Indapamide

"Azithromycin may increase the QTc-prolonging activities of Indapamide."

Clinical Note

moderate

Azithromycin + Artesunate

"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Azithromycin resulting in a loss in efficacy."